Suven Pharmaceuticals
SUVENPHAR · Pharma > Pharmaceuticals & Drugs · Chairman: Venkateswarlu Jasti · MD: Venkateswarlu Jasti · Listing date: March 10, 2020 · Employees: 1114 · Hyderabad · http://www.suvenpharm.com

Stock Price vs Company Growth
1d
0.3%
1w
2.0%
1m
1.2%
3m
3.1%
6m
20.8%
1y
42.5%
all
40.4%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 671 0.3%
586
731
Company Overview

Sales
1,168 Cr
Growth: -2.3%
Profit after Tax
371 Cr
Growth: -14.1%
Mid Cap
17,086 Cr
P/E: 46.0x
Industry P/E: 35.0x
Fundamentals

Sales (Cr) ₹ 1,168
Growth -2.3%
EBITDA 42.7%
P/S 14.6x
Dividend 0.0%
P/E 46.0x
Book Value ₹ 77.9
PEG Ratio -20.5x
ROE 19.8%
P/B 8.6x
Shareholding Pattern

Institutions
Uti Small Cap Fund
2.17 %
L And T Mutual Fund Trustee Ltd-L And T Mid Cap Fund
1.95 %
Promoters
Jasti Property And Equity Holdings Private Limited(Initscapacityassoletrusteeofjastifamilytrust)
60.0 %
Others
Rambabu Chirumamilla
2.14 %
Qualified Institutional Buyer
0.7 %
Iepf
0.14 %
Increase    Decrease    No change
Company Profile Detailed

The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc.
Investors (27)
Followers (3)